Psoriasis drug combo aims to tackle skin and cholesterol in one shot
NCT ID NCT07373847
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial tests whether adding recaticimab to vunakizumab works better than vunakizumab alone for adults with moderate-to-severe plaque psoriasis and high cholesterol. Forty participants will be randomly assigned to receive either the drug combo or vunakizumab plus a placebo. The main goal is to see how many achieve completely clear skin by week 16.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vunakizumab and recaticimab
What this could lead to
If successful, this combination could offer a new treatment option that controls both psoriasis and high cholesterol at the same time.
What could go wrong
This is a small, early-phase trial with only 40 people. The combination may not work better than vunakizumab alone, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••